bsm-54143R [Primary Antibody]
FTO (12A1) Monoclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: FTO

Clonality: Monoclonal

Isotype: IgG

Entrez Gene: 79068

Swiss Prot: Q9C0B1

Source: Recombinant protein within human FTO aa 350-500

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at 4°C for up to 2 weeks. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.

Background:

RNA demethylase that mediates oxidative demethylation of different RNA species, such as mRNAs, tRNAs and snRNAs, and acts as a regulator of fat mass, adipogenesis and energy homeostasis. Specifically demethylates N6-methyladenosine (m6A) RNA, the most prevalent internal modification of messenger RNA (mRNA) in higher eukaryotes. M6A demethylation by FTO affects mRNA expression and stability. Also able to demethylate m6A in U6 small nuclear RNA (snRNA). Also acts as a tRNA demethylase by removing N1-methyladenine from various tRNAs. Also able to repair alkylated DNA and RNA by oxidative demethylation. Involved in the regulation of fat mass, adipogenesis and body weight, thereby contributing to the regulation of body size and body fat accumulation. Involved in the regulation of thermogenesis and the control of adipocyte differentiation into brown or white fat cells. Regulates activity of the dopaminergic midbrain circuitry via its ability to demethylate m6A in mRNAs. Plays an oncogenic role in a number of acute myeloid leukemias by enhancing leukemic oncogene-mediated cell transformation: acts by mediating m6A demethylation of target transcripts such as MYC, CEBPA, ASB2 and RARA, leading to promote their expression

Size: 100ul

Concentration: 1ug/ul

Predicted Molecular Weight: 58


Cross Reactive Species: Human

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Lane 1: Human Fetal Brain; Lane 2: HepG2 Cells; Lane 3: 293 Cells; Probed with FTO (12A1) Monoclonal Antibody (bsm-54143R) at 1:1000 overnight at 4°C followed by a conjugated secondary antibody for 60 minutes at 37°C.


Paraformaldehyde-fixed and paraffin-embedded Human Placenta tissue incubated with FTO (12A1) Monoclonal Antibody (bsm-54143R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.


Paraformaldehyde-fixed and paraffin-embedded Human Pancreas tissue incubated with FTO (12A1) Monoclonal Antibody (bsm-54143R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.


Paraformaldehyde-fixed and paraffin-embedded Human Uterus tissue incubated with FTO (12A1) Monoclonal Antibody (bsm-54143R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.


IF(ICC) staining with FTO (12A1) Monoclonal Antibody (bsm-54143R) at 1:100 in Hela cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100/PBS.


IF(ICC) staining with FTO (12A1) Monoclonal Antibody (bsm-54143R) at 1:100 in A549 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100/PBS.